Imugene Limited

IMU

Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialization of immunotherapies against cancer. The company is headquartered in Sydney, New South Wales. The company is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.

Pilbara Minerals Limited

PLS

Pilbara Minerals Ltd. engages in the provision of exploration and evaluation of mineral properties. The company is headquartered in Perth, Western Australia and currently employs 917 full-time employees. The company went IPO on 2007-09-19. The firm owns 100% of an independent hard-rock lithium operation, the Pilgangoora operation in Australia, and the Colina Project in Brazil. Its Pilgangoora operation is located 140 kilometers (kms) from Port Hedland in Western Australia’s resource rich Pilbara region on Nyamal and Kariyarra Country. Spodumene concentrate from its Pilgangoora operation is shipped from Port Hedland, the bulk export port, to lithium chemical converters primarily in China. The firm's Colina project is located 10 kms from the town of Salinas in the world class mining jurisdiction of Minas Gerais, Brazil. The firm is also integrated into the lithium value chain through its joint venture with POSCO in South Korea, which manufactures battery-grade lithium hydroxide.

Vanguard Diversified High Growth Index ETF

VDHG

VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

VanEck MSCI International Sustainable Equity ETF

ESGI

ESGI.AX was created on 2018-03-06 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to provide investment returns before fees and other costs which track the performance of its Reference Index in Australian dollars.

VanEck MSCI Australian Sustainable Equity ETF

GRNV

GRNV.AX was created on 2016-04-27 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. GRNV.AX gives investors access to a diversified portfolio of sustainable Australian companies selected on the basis of in-depth analysis by world leading research agency MSCI ESG Research. GRNV.AX aims to provide investment returns, before fees and other costs, which track the performance of the Index.